These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29289700)

  • 1. Adherence to synthetic disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the OBSERVAR Study.
    Juan Mas A; Castañeda S; Cantero Santamaría JI; Baquero JL; Del Toro Santos FJ;
    Reumatol Clin (Engl Ed); 2019; 15(5):264-270. PubMed ID: 29289700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review.
    Calvo Alén J; Pérez T; Romero Yuste S; Ferraz-Amaro I; Alegre Sancho JJ; Pinto Tasende JA; Maceiras Pan F; Quevedo JC; Hernández-Hernández MV; Hidalgo Calleja C; San Martín Álvarez A; Sánchez MIT; Sanmartí R
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):324-332. PubMed ID: 30241955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations by the Spanish Society of Rheumatology for the management of patients diagnosed with rheumatoid arthritis who cannot be treated with methotrexate.
    García-Vicuña R; Martín-Martínez MA; Gonzalez-Crespo MR; Tornero-Molina J; Fernández-Nebro A; Blanco-García FJ; Blanco-Alonso R; Marsal-Barril S;
    Reumatol Clin; 2017; 13(3):127-138. PubMed ID: 27825791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.
    Sanmartí R; García-Rodríguez S; Álvaro-Gracia JM; Andreu JL; Balsa A; Cáliz R; Fernández-Nebro A; Ferraz-Amaro I; Gómez-Reino JJ; González-Álvaro I; Martín-Mola E; Martínez-Taboada VM; Ortiz AM; Tornero J; Marsal S; Moreno-Muelas JV
    Reumatol Clin; 2015; 11(5):279-94. PubMed ID: 26051464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis.
    McCulley C; Katz P; Trupin L; Yelin EH; Barton JL
    J Rheumatol; 2018 Dec; 45(12):1636-1642. PubMed ID: 30219761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis.
    Mjaavatten MD; Radner H; Yoshida K; Shadick NA; Frits ML; Iannaccone CK; Kvien TK; Weinblatt ME; Solomon DH
    J Rheumatol; 2014 Dec; 41(12):2370-8. PubMed ID: 25320216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclinical synovitis and tenosynovitis by ultrasonography (US) 7 score in patients with rheumatoid arthritis treated with synthetic drugs, in clinical remission by DAS28.
    Ventura-Ríos L; Sánchez Bringas G; Hernández-Díaz C; Cruz-Arenas E; Burgos-Vargas R
    Reumatol Clin (Engl Ed); 2019; 15(5):e5-e9. PubMed ID: 29198500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs.
    van den Bemt BJ; van den Hoogen FH; Benraad B; Hekster YA; van Riel PL; van Lankveld W
    J Rheumatol; 2009 Oct; 36(10):2164-70. PubMed ID: 19723906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project.
    Muñoz-Fernández S; Bustabad Reyes MS; Calvo Alén J; Castaño Sánchez M; Chamizo Carmona E; Corominas H; Fernández-Llanio Comella N; Hidalgo Calleja MC; Pérez Venegas JJ; Rodríguez Heredia JM; Romero Yuste SM; Ruiz-Esquide Torino V;
    Reumatol Clin (Engl Ed); 2018; 14(2):90-96. PubMed ID: 28065486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.
    Tornero-Molina J; Alperi-López M; Castellví I; de Agustín-de Oro JJ; Escudero A; García-Vicuña R; González-Gay MÁ; Hidalgo C; Rubio E; Sanmartí R; Casamira N; Calvo-Alén J
    Reumatol Clin (Engl Ed); 2022 Jan; 18(1):33-41. PubMed ID: 35090610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature.
    Salt E; Frazier SK
    Orthop Nurs; 2010; 29(4):260-75. PubMed ID: 20664466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.
    Alfaro-Lara R; Espinosa-Ortega HF; Arce-Salinas CA;
    Reumatol Clin (Engl Ed); 2019; 15(3):133-139. PubMed ID: 28867467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient's perspective.
    Pascual-Ramos V; Contreras-Yáñez I
    BMC Musculoskelet Disord; 2013 Dec; 14():336. PubMed ID: 24289729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.